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Abstract: Diabetes mellitus (DM) is one of the oldest known human disease currently affecting more than 200 million 
people worldwide. Diabetes mellitus is derived from two Greek words meaning siphon and sugar. In DM, patients have 
high blood level of glucose and this passes out with urine. This is because the endocrine pancreas does not produce either 
or not enough insulin or the insulin which is produced is not exerting its biochemical effect (or insulin resistance) effec-
tively. Insulin is a major metabolic hormone which has numerous functions in the body and one main role is to stimulate 
glucose uptake into body’s cells where it is utilized to provide energy. The disease is classified into type 1 and type 2 DM. 
Type 1 DM develops when the insulin producing  cells have been destroyed and are unable to produce insulin. This is 
very common in children and is treated with insulin. Type 2 DM (T2DM) develops when the body is unable to produce an 
adequate amount of insulin or the insulin which is provided does not work efficiently. This is due to life style habits in-
cluding unhealthy diet, obesity, lack of exercise and hereditary and environmental factors. Some symptoms of DM include 
excess urination, constant thirst, lethargy, weight loss, itching, decreased digestive enzyme secretion, slow wound healing 
and other related symptoms. If left untreated, DM can result in severe long-term complications such as kidney and heart 
failure, stroke, blindness, nerve damage, exocrine glands insufficiency and other forms of complications. T2DM can be 
treated and controlled by prescribed drugs, regular exercise, diet (including some plant-based food) and general change in 
life style habits. This review is concerned with the role of plant-based medicine to treat DM. One such plant is Momordica 
charantia which is grown in tropical countries worldwide and it has been used as a traditional herbal medicine for thou-
sands of years although its origin in unknown. This review examines the medicinal chemistry and use(s) of M. charantia 
and its various extracts and compounds, their biochemical properties and how they act as anti-diabetic (hypoglycemic) 
drugs and the various mechanisms by which they exert their beneficial effects in controlling and treating DM. 
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INTRODUCTION  
  Diabetes mellitus (DM) is one of the oldest known hu-
man disease currently affecting about 200 million people 
worldwide [1]. It is estimated that by 2025, more than 300 
people globally will have confirmed DM and other 50 mil-
lion undiagnosed [2, 3]. This disease is the most common 
metabolic disorder in human and it is characterized by hy-
perglycemia, due to relative or absolute lack of insulin, the 
insensitivity of insulin or both [4, 5]. DM is classified into 
type 1 or insulin-dependent DM (IDDM) or type 2 or non-
insulin dependent DM (NIDDM) or T2DM [5, 6]. Type 1 
DM represents about 5-10% of all cases of DM whereas   
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T2DM accounts for 90-95% of diabetes. Type 1 DM is char-
acterized mainly by auto-immune-mediated destruction of 
beta cells of the endocrine pancreas leading to reduced insu-
lin secretion. This form of DM is prevalent in young children 
[5, 7]. On the other hand, T2DM is characterized by insulin 
resistance and relative insulin deficiency and it is due to sed-
entary life style, genetic disposition, obesity, human behav-
ior and environmental factors. Both forms of DM can lead to 
such long-term complications as neuropathy, retinopathy, 
cardiomyopathy, nephropathy, exocrine gland insufficiency 
and several other complications and eventually to death [5]. 
Type 1 DM is treated mainly with insulin whereas T2DM is 
controlled by hypoglycemic drugs, regular exercise, general 
change in life style habits and diet including some plant-
based food. The plant kingdom is a good potential source for 
the discovery of novel medicines to treat numerous diseases 
including DM. Currently, about 400 plants incorporated 
more than 700 recipes and compounds which have been Diabetes Mellitus and Momordica charantia  The Open Medicinal Chemistry Journal, 2011, Vol. 5    71 
evaluated extensively for the treatment of diabetes through-
out the world [8-14]. In many parts of the world, especially 
in poor countries, this may be the only available form of 
therapy for the treatment of diabetic patients. One such plant 
is Momordica charantia (family name: Cucurbitaceae), na-
ture’s own cure for DM. M. charantia has been used exten-
sively as an anti-viral, anti-bacterial agent and more so to 
treat a number of infections and diseases [13]. These include 
DM, indigestion, fever, skin disease, HIV, viral and bacterial 
infections, hypertension, reduced cholesterol and inflamma-
tion, detoxification of the body, expelling worms from the 
body, balance certain hormones in the body, enhances im-
munity, promotes milk flow, prevents different tumors and 
several other reported medicinal benefits. This review is 
concerned specifically with the medicinal chemistry of M. 
charantia and its extracts and active constituents to treat 
DM. 
PLANT-BASED ANTI-DIABETIC MEDICINE 
  Plant-based medicine has been used cost-effectively 
worldwide to treat DM. In fact, in many parts of the world, 
especially poor countries, this may be the only form of ther-
apy available to treat diabetic patients. There are several re-
views by different authors about anti-diabetic herbal plants 
[9-11, 13, 15-17]. One review has listed more than 300 plant 
species which possess hypoglycemic properties and classi-
fied them according to their biochemical names, country of 
origin, parts used and nature of the active agent(s) [11]. 
From the current literature, it is evident that M. charantia is 
the most widely used and popular anti-diabetic plant. Thus, 
this review will concentrate mainly on M. charantia and its 
anti diabetic properties [13]. 
CHARACTERISTICS OF M. CHARANTIA 
Scientific name: Momordica charantia 
Kingdom: Plantae 
Division: Magnoliophyta 
Family: Cucurbetaceae 
Genus: Momordica 
Species: Charantia 
Duration: Annual 
  Some common names of M.charantia include bitter 
melon, papilla, bitter gourd, salsamino, corrila or karela, 
hanzal, assorossie, ampalaya, nigauri or goya, pare, kho gua, 
sora, balsam apple, pear or balsamina, and several other 
common names (see Taylor, 2002 [13] for extensive review 
and technical data). M. charantia is cultivated in many damp 
and wet tropical countries of the world including parts of 
South America and the Amazon basin including Brazil, 
Guyana and the Caribbean, East Africa and Asia including 
India, China, Philippines, Pakistan, Nepal and Sri Lanka. M. 
charantia is harvested both as food and as a medicine. It is a 
slender annual climbing vine with long leaves and at repro-
ductive stage it produces warty or wrinkled gourd green 
fruits, resembling a squash or a cucumber. M. charantia is 
known for its very bitter taste and this is found in the leaves, 
the fruits, the stems and other parts of the plant [17]. The 
bitter taste is a distraction for eating the fruit but this is 
sometimes overshadowed by its beneficial effect. People 
normally boil the green leaves and stem and drink the bitter 
content as tea. Some people cook the fruit as a curry or with 
meat, while others eat it as a salad, fried it in oil or liquidize 
it into a herbal juice. In some cases people neutralize the 
bitter taste with the addition of a fruit (e.g. papaya) or a 
tropical juice such as mango or with a dash of salt. Commer-
cially, the plant is used to make a powder which is sold 
commercially as tea or as in capsule form. Medicinally, the 
plant, its fruit and its powder extract possess a long history 
of use in the treatment of numerous diseases including diabe-
tes [9-11,13,15,17].  
    
EXTRACTS AND ACTIVE INGREDIENTS OF   
M. CHARANTIA 
  Generally, the public have used different parts of M. 
charantia  including the leaves, the stem and mainly the 
green fruits or seeds to treat diabetes. Table 1 shows the 
chemical structures of momocharin (1) and momordicin (2) 
which is believed to possess insulin-like chemical structure 
and properties. People eat the fruit raw, boil or cook the dif-
ferent parts or drink the pulp of the fruit as a juice. Over the 
years several scientists have tried to isolate the various active 
ingredient of M. charantia for commercial purpose.  
Table 1. Chemical Structure of Momorcharin and Momorcidin 
# Chemical  Structure 
(1) Momorcharin 
CH3
H3C CH3
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CH3
CH3
 
(2) Momordicin 
O
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H3C CH3
OH
CH3
CH3
H3C
OH
CH3
CH3
 
 
Fig. (1) shows a schematic diagram of the different stages of 
the isolation procedure for the active ingredient(s) of M. 
charantia fruit employing water and organic solvents. Ini-
tially, the fruits are chopped into small pieces and liquidized 
in deionized water. The green supernatant is separated from 
the cellulose and subsequently, the water is extracted using a 
rota-evaporator. The residue is dried in an oven and the 
green powder extract is used for experimentation or for fur-
ther extraction, purification and identification employing 
HPLC, affinity chromatography, SDS-PAGE and NMR mass 
spectroscopic methods. Two medicinal compounds extracted 
from  M.  charantia include, charantin, a steroidal saponin 
agent with insulin-like properties and momordicin (2), an 72    The Open Medicinal Chemistry Journal, 2011, Vol. 5  Singh et al. 
alkaloid responsible for the bitterness of the fruit [18]. In 
laboratory and clinical in vitro and in vivo studies scientists 
and clinicians have employed different water, ethanol and 
ether extracts as well as isolated biologically active phyto-
chemicals including glycosides (momordin and charantin), 
alkaloids (momordicin (2)), polypeptide-P, oils from the 
seeds (linoleic, stearic and oleic acids), glycoproteins (alpha–
momorcharin (1), beta-momorcharin and lecitins) and others 
active compounds including protein MAP30 and vicine 
(pyrimidine nuclease) to study their hypoglycemic properties 
using both human and animal models [13]. Of these con-
stituents, charantin, insulin-like peptides and alkaloids pos-
sess hypoglycemic properties. They are more effective when 
they are combined and they produce effects almost similar to 
the crude water soluble extract [13]. 
COMPOUNDS PRESENT IN M. CHARANTIA 
  Today around 228 different medicinal compounds have 
been isolated from the stems, leaves, pericap, entire plant, 
aerial parts of the plant, endosperm, callus tissues, cotyle-
dons and mainly the seeds and unripe fruit in different labo-
ratories in India, Japan, USA, Thailand, Egypt, China, Tai-
wan, Australia, Nigeria, Pakistan, Brazil, Nepal, Philippines 
and Peru [19].  
  These different compounds have been classified into dif-
ferent chemical types. These includes proteids, triterpenes, 
lipids, inorganic compounds, phenylpropanoids, carotenoids, 
steroids, alkaloids, monoterpenes, alkene to C3, carbohy-
drates, benzanoids, alkanol C5 or more, other unknown 
structure (e.g. kakara I-B, II-A and III-B) sterol and ses-
quiterpene. Of the 228 different compounds, most of these 
fall under the groups of proteids and triterpenes [13].  
  The plant has many different chemical components, 
which help medicinally either alone or when combined. One 
of the hypoglycemic components is a steroid saponin called 
momocharin (charantin) (1) with insulin-like chemical effect. 
Charantin has a molecular weight of 9.7 kDa and it is the 
belief that charantin is the active hypoglycaemic agent of M. 
charantia.  
Table 2 shows similarities in the chemical structures of mo-
mocharin (1), momordicin (2) and other commercially avail-
able hypoglycemic drugs (glibenclamide (3), gliclazide (4), 
Glipizide (5), Metformin hydrochloride (6), Pioglitazone 
hydrochloride (7) used in the treatment of T2DM. The hypo-
glycemic action of M. charantia and its isolated components 
may be due to its insulin-like structure. Recently, two other 
anti-diabetic constituents were isolated from M. charantia 
and both substances exerted hypoglycemic effects in mice. 
The cucurbitane triterpenoids were found to have the struc-
tures, 5, 19-epoxycucurbita-6, 5, 19-epoxy-19, 25-
dimethoxycucurbita-6 23-(E)-dien-3-ol and 3-7-25-
trihydroxy-cucurbita-5, 23 (E)-dien-19-al. These two com-
pounds have more or less the same parent structure as - 
momocharin (1), and momordicin (2) [20]. More recently, 
momordicin 1 (2) was isolated from M. charantia and its 
chemical structure was characterized as momordicin1 3, 7, 
23,-Trihydroxycucurbitan-5,24-dien-19-al [20]. This com-
pound is more or less similar to the one identifies by Hari-
nantenaina et al. [21]. 
TRADITIONAL REMEDY  
  The literature has suggested that one-half of one cup of a 
standard leaves or whole herb concoction, 1-2 times daily is 
adequate for a hypoglycemic effect. Alternatively, an amount 
of one to two grams of the water extracted powder from ei-
ther the leaf or fruit is adequate as a daily dose. Many people 
liquidize two to three green fruits with water or with a tropi-
cal juice and drink 10 to 20 ml twice per day prior to meal. 
 
Fig. (1). Schematic diagram showing the isolation procedures for the active ingredient(s) of M. charantia fruit juice (redrawn from Day et al 
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The question which people often ask is: can they take M. 
charantia  with traditional commercial anti-diabetic drugs? 
The answer is to discuss the matter with their General Practi-
tioner first. There may be an element of drug interaction be-
tween M. charantia and commercially available anti-diabetic 
glucose lowering drugs but further experiments are required 
to determine the kind of interaction which may occur be-
tween a commercially available hypoglycemic drug and M. 
charantia or its hypoglycaemic extract [22]. For people with 
T2DM there is no harm in using M. charantia alone, but 
combine this regimen with regular physical exercise and 
modification of daily diet. Previous studies have described 
the pharmacology, clinical efficacy, adverse effects, drug 
interactions and place in therapy of M. charantia [22]. It is 
particularly noteworthy that M. charantia is an alternative 
herbal therapy that has been used primarily to reduce blood 
glucose level for thousands of years in patients with DM. 
Regarding adverse effects, some studies have reported hypo-
glycemic coma and convulsions in children, reduced fertility 
in mice, a fetish-like syndrome, increase in gamma glutamyl-
transferase and alkaline phosphatase levels in animals and 
some headaches [22]. 
CLINICAL AND BASIC EXPERIMENTAL STUDIES 
  Over the past 50 years, both basic and clinical studies 
have been done to determine the effect of M. charantia on 
the management of DM. Table 3 shows the effect of oral 
administration of M. charantia on both animal and human 
type 2 models. Today the literature contains over 40 studies 
employing adult human subjects and another 100 have em-
ployed animal models. They were administered with a hot 
water extract, concoction, the fruit, the fruit juice or the 
seeds [13]. Typically, of the twenty or more studies present 
in Table 3, only three have demonstrated no beneficial ef-
fects, one on T2DM patient [16], one in rabbit [23] and the 
other in rat [24]. However, the other seventeen studies have 
successfully demonstrated that the whole plant, ethanol ex-
tract, fruit juice, powder, concoction or seed can evoke hy-
poglycemic effects. The reason for the three unsuccessful 
findings may be due to the fact that the authors employed 
high doses of M. charantia. Previous studies have success-
fully demonstrated that M. charantia is more beneficial as a 
hypoglycemic agent only at therapeutic doses. Either phar-
macological or high doses of M. charantia seem to exert 
inhibitory effects [17, 25]. To date, not much study have 
been done on purified components of M. charantia in both 
human and animal models. 
POSSIBLE MODES OF ACTION OF M. CHARANTIA 
AND ITS EXTRACT 
 M.  charantia  and its various extracts and components are 
believed to exert their hypoglycemic effects via different 
physiological, pharmacological and biochemical modes [13, 
15, 17, 33]. Table 4 lists some possible modes of the hypo-
glycemic actions of M. charantia and its various extracts and 
compounds. Today over 140 different studies worldwide 
[13] have investigated anti-hyperglycemic and hypoglycemic 
effects of the different extracts and ingredients of M. charan-
tia in both human and animal models. These include the fruit 
extracts with, either hot water, ethanol, lyophilized, benzene, 
chloroform, acetone, fruit juice and powder. Of all the differ-
ent studies, about 120 have reported active and beneficial 
effects, whereas the remaining 20 have reported inactive or 
no beneficial effects. There are several reasons for these dis-
Table 2.  Chemical Structures of Momorcharin (1), Momor-
dicine (2), Glibenclamide (3), Gliclazide (4), Glipiz-
ide (5), Metformin Hydrochloride (6), Pioglitazone 
hydrochloride (7). Note similarities in structure 
momorcharin and Momordicin and Hypoglycemic 
agents 
# Chemical  Structure 
(1) Momorcharin 
CH3
H3C CH3
Glucose
CH3
CH3
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O
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crepancies in the activity of M. charantia and its various 
extracts and isolated compounds. These may be due to the 
duration (short time period) of the experiments, doses of the 
compounds (high doses seem to evoke inhibitory or toxic 
effect) [32], the animal models and gender employed in the 
studies, the method of application/administration, and in 
some cases the laboratories and countries where the work 
was done and also the extracts administered. These discrep-
ancies may also be due to seasonal variations [13]. 
 M.  charantia,  its extracts and isolated components are 
believed to exert their hypoglycaemic effects via different 
physiological and biochemical processes. These include in-
sulin secretagogue like effect, stimulation of skeletal muscle 
and peripheral cell glucose utilization, inhibition of intestinal 
glucose uptake, inhibition of hexokinase activity, suppres-
sion of key gluconeogenic enzymes, stimulation of key en-
zymes, HMP pathway and preservation of pancreatic islet 
cells and their functions (see Table 4 for relevant references). 
PRESERVATION OF PANCREATIC  CELLS AND 
INSULIN SECRETION 
  It was previously demonstrated by Jeewathayaparan et al. 
[25] that oral administration of M. charantia could lead to 
the secretion of insulin from endocrine pancreatic beta cells. 
This observation was further confirmed by Ahmed et al. [33, 
39, 41] who investigated the effect of daily oral administra-
tion of M. charantia fruit juice and the distribution of ,  
and  cells in the pancreas of streptozotocin (STZ)-induced 
diabetic rats using immunohistochemical methods. In these 
studies, they observed that M. charantia significantly in-
creased the number of  cells compared to untreated diabetic 
rats. However, the number of  cells was significantly less 
than that obtained in normal and M. charantia-treated con-
trol rats. This may be due to the fact that the study was only 
done for a period of 10 weeks and moreover, the STZ proba-
bly destroyed some of the beta cell completely one week 
prior to the administration of the fruit juice to the animals. 
From these studies, the authors concluded that M. charantia 
fruit juice may have a role in the renewal of  cells in treated 
diabetic rats or alternatively, the juice may permit the recov-
ery of partially destroyed  cells [33, 39, 41]. Physiological 
experiments have also shown that M. charantia can stimulate 
insulin secretion from the endocrine pancreas [42] and elicit 
glucose uptake in the liver [43]. Current evidence therefore 
indicates that the recovery and subsequent increase in the 
number of insulin producing cells followed by the release of 
insulin may be part of the several pathways by which M. 
charantia exerts its hypoglycemic effects. In addition to the 
properties mentioned above, M. charantia and its extracts 
may possess cell-like proliferation and growth-like proper-
ties similar to that of insulin [5, 25]. Nevertheless, further 
experiment are required, at least at the molecular level, to 
determine the precise mechanisms whereby M. charantia can 
either repair damaged  cells or prevent their death. 
M. CHARANTIA AND GLUCOSE METABOLISM 
  Insulin plays a major biochemical role in stimulating the 
uptake of glucose by different cells of the body for the pro-
duction of energy [4, 5, 25]. Since M. charantia and its vari-
ous extracts and components have been reported to exert 
hypoglycemic effects, then it is important to understand 
whether M. charantia may have a direct effect in inducing a 
reduction in blood glucose level [13]. Previous studies have 
shown that both the aqueous and alcoholic extracts of the 
fruit of M. charantia can inhibit the activities of fructose 1, 
Table 3.  Effects of Oral Administration of M. charantia on Diabetes Mellitus 
Experimental Models  Parts of Plant used  Effects   References  
Normal and diabetic rats  Whole plant   Beneficial   Leatherdale et al. [26] 
Jeevathayaparan et al. [27] 
Chandrasekar et al. [28] 
Diabetic rats  Ethanol extract of whole 
plant 
Beneficial Chandrasekar  et al. [29] 
Normal and diabetic rats  Fruit juice and various ex-
tracts 
Beneficial Ali  et al. [30, 31] 
Human (NIDDM)  Fruit juice/leaves  Beneficial  William and Pickup [6]; Ahmad et al. [45] 
Human (NIDDM)  Fruit juice  No effect  Patel et al. [12], Day and Bailey [8] 
Human (NIDDM)  Fruit powder  Beneficial  Akhtar et al. [32], Ahmed et al. [33] 
Normal rabbits  Fruit juice  No effect  Kulkarni et al. [23] 
Diabetic rabbits  Fruit juice  Beneficial  Akhtar et al. [32] 
Normal and diabetic rats  Fruit juice  No effect  Karunanayake et al. [24] Platel and Srinivasan 
[16, 17]  
Normal and diabetic rats  Fruit juice  Beneficial  Srivastavaet et al. [49]: Karunanayake et al. [24] 
Normal and diabetic rat   Fruit juice  Beneficial  Sharma et al. [37]; Day et al. [19] 
Normal and diabetic rats  Seed   Beneficial  Kedar and Chakrabarti [35] 
Normal and diabetic rats  Fruit juice  Beneficial  Sharma et al. [34] Diabetes Mellitus and Momordica charantia  The Open Medicinal Chemistry Journal, 2011, Vol. 5    75 
6-diphosphatase and glucose-6-phosphatase and at the same 
time stimulating the action of glucose-6-phosphatase dehy-
drogenase [17, 19, 34, 36]. It was previously reported that M. 
charantia  and its various extracts can stimulate peripheral 
cell glucose uptake [17, 19, 25]. A number of studies have 
investigated the effect of the powder and chloroform extract 
of M. charantia in comparison with insulin on glucose and 
amino acid uptakes by skeletal L6 myotubes and Na
+ and K
+ 
glucose uptakes by jejunum brush border membrane vesicles 
in both age-matched control and STZ-induced diabetic rats. 
The results show that either the lyophilized fruit juice or 
chloroform extract at 5-10 μg ml
-1 can stimulate 
3H-
deoxyglucose and 
14C–Me AIB (N-methyl-amino--
isobutyric acid) uptakes by L6 myotubes. These effects were 
similar in magnitude to the effects obtained with 100 nM 
insulin. Incubation of either insulin or M. charantia juice in 
the presence of wortmannin (a phosphatidylinositol 3-kinase 
inhibitor) resulted in a marked inhibition of 
3H-deoxyglucose 
uptake by L-6 myotubes [25, 44]. Together, the results have 
clearly demonstrated that M. charantia contains insulin like 
properties, similar  to one phytochemical component of M. 
charantia called V-insulin [13]. 
  In addition to its insulin-like effects on skeletal muscle 
cells, daily oral intake of M. charantia fruit juice over a pe-
riod of 10 weeks significantly reduced the amount of Na
+ 
and K
+-dependent 
14C-D-glucose absorbed by rat jejunum 
brush border membrane vesicle compared to vesicles ob-
tained from STZ-induced diabetic rats [33,41]. Taken to-
gether, these results clearly demonstrated that M. charantia 
and its extracts can directly regulate blood glucose via two 
mechanisms. Firstly, it can regulate how much glucose is 
absorbed by the gut into the blood following a meal and sec-
ondly, it can stimulate glucose uptake into skeletal muscle 
cells just like insulin. Moreover, it seems to exert its effect 
via the same intracellular signaling pathways as insulin in 
regulating glucose metabolism in the body [44].  
ANTI NEUROPATHIC EFFECT OF M. CHARANTIA 
FRUIT JUICE 
  Human diabetic neuropathy is both cumbersome and 
complicated and it may result in severe disability [5, 6]. In 
addition, treatment of diabetic neuropathy is very expensive. 
The most cost effective way is to either prevent or delay the 
onset of this, long-term diabetic complication. The influence 
of  M. charantia fruit extract and insulin on the ultra-
structural abnormalities of myelinated fibers in experimental 
diabetes in rats was investigated in previous studies [33, 37, 
40]. 
  The results have shown that the mean cross-sectional 
myelinated fibre area, axonal area and myelin area including 
the mean maximum myelinated fibres area were significantly 
less in untreated diabetic rats when compared with age-
matched controls. In the M. charantia treated diabetic ani-
mals, myelinated fibre area and myelin area were signifi-
cantly greater than untreated diabetics and not significantly 
different from age-matched controls. The mean value for the 
maximum fibre area was also significantly greater than un-
treated diabetics and was not significantly different from 
age-matched controls. The axon to fibre ratio (‘g’ ratio) did 
not differ between any of the experimental groups. It was 
concluded that the administration of M. charantia fruit juice 
not only reduced blood glucose level but also corrected the 
structural abnormalities of peripheral nerves in experimental 
diabetes. These results have strongly indicated that M. 
charantia  possesses growth factor-like properties just like 
insulin [5, 31, 37, 39].  
 To  date,  M. charantia has been extensively studies 
worldwide for its medicinal properties to treat a number of 
diseases [38]. It is described as a versatile plant worthy of 
treating almost any disease inflicted on mankind. This may 
be due to the fact the plant possesses over 225 different me-
dicinal constituents [13]. These different compounds may act 
either separately or together to exert their medicinal effects. 
In relation to diabetes [46], only charantin, insulin-like pep-
tide and alkaloid-like extracts possess hypoglycemic proper-
ties similar to the plant itself or its crude extracts. These dif-
ferent compounds seem to exert their beneficial effects via 
several mechanisms to control and treat diabetes mellitus. 
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